New immunodiagnostic methods for human tegumentary leishmaniasis in the last 10 years: Technological prospecting

Acta Trop. 2023 Jun:242:106903. doi: 10.1016/j.actatropica.2023.106903. Epub 2023 Mar 24.

Abstract

Leishmaniasis is a neglected disease and more than 1 billion people live in endemic areas with the risk of infection worldwide. Although it is an important epidemiological issue, the gold standard method of diagnosis requires invasive sample collection and is accompanied by a high level of sensitivity variation in results. The present study aims to conduct a patent prospection of immunodiagnostic methods for human tegumentary leishmaniasis in the last 10 years, focused on those with high sensitivity and specificity, and simple usability. We searched seven patent databases: The LENS, WIPO, EPO, USPTO, Patent Inspiration, Google patents, and INPI. Eleven patents were found that satisfy our search criteria, with six of them being registered in 2017. Most patents were registered in Brazil. The information obtained here covers the main characteristics of the immunodiagnostic methods evaluated. Moreover, our prospective study reveals the latest biotechnological advancements achieved in the immunodiagnosis of tegumentary leishmaniasis, especially in Brazil, which holds the majority of patents in this subject. However, no patent for immunodiagnostic methods was found in the last three years, which raises concerns about the present and future trends of leishmaniasis diagnosis.

Keywords: Cutaneous leishmaniasis; Immunodiagnosis; Patents; Technological prospecting.

Publication types

  • Review

MeSH terms

  • Brazil
  • Humans
  • Leishmaniasis* / diagnosis
  • Leishmaniasis, Cutaneous* / diagnosis
  • Prospective Studies